QED THERAPEUTICS
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
QED THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.qedtx.com
Total Employee:
11+
Status:
Active
Contact:
1-877-280-5655
Email Addresses:
[email protected]
Total Funding:
65 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Wordpress Plugins Euro
Similar Organizations
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Sonnet BioTherapeutics
Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action.
Current Employees Featured
Investors List
BridgeBio Pharma
BridgeBio Pharma investment in Venture Round - QED Therapeutics
Official Site Inspections
http://www.qedtx.com
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
